Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

National City, California 91950


Purpose:

Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.


Criteria:

Inclusion Criteria: - Patients must have a diagnosis of one of the following complicated skin and skin structure infections with Methicillin Resistant Staphylococcus aureus (MRSA) either suspected or confirmed as the major cause of the infection: - major abscess requiring surgical incision and drainage - infected burn (see exclusion criteria for important qualifications) - deep/extensive cellulitis - infected ulcer (see exclusion criteria for important qualifications) - wound infections - Patients must be expected to require at least 7 days of intravenous antibiotic treatment Exclusion Criteria: - Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy prior to randomization - Burns involving > 20% of body surface area or third-degree/full-thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fascitis, gas gangrene, or mediastinitis.


NCT ID:

NCT00091819


Primary Contact:

Principal Investigator
G. Ralph Corey, MD
Duke University


Backup Contact:

N/A


Location Contact:

National City, California 91950
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 15, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.